Global Contact Lens Market 2016-2020

2016-05-19
Price :
Published : May-2016
No. of Pages : 84

Contact lenses are a replacement for corrective glasses due to their better aesthetic and cosmetic appeal. They are thin lenses that are placed directly on the surface of the eye and are worn to correct vision or for other therapeutic purposes. They are also worn for cosmetic reasons, particularly to change eye color.

Contact lenses can be rigid, soft, or hybrid in nature, depending on the composition of the materials used. The advantages of contact lens over corrective glasses make them suitable to wear in any weather conditions, outdoor activities, or sports.

The analysts forecast global contact lens market to grow at a CAGR of 6.63% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global contact lens market for 2016-2020.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • Europe
  • MEA

The report, Global Contact Lens Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Cooper
  • Johnson & Johnson
  • Novartis
  • Valeant Pharmaceuticals

Other prominent vendors

  • All Pro Intraocular Lens
  • Blanchard
  • Carl Zeiss
  • Conforma
  • Contamac
  • Essilor
  • Hoya
  • Medennium
  • Menicon
  • Shanghai Hydron Contact Lens Optics
  • Synergeyes
  • UltraVision

Market driver

  • Rise in the number of people with eye disorders
  • For a full, detailed list, view our report

Market challenge

  • Risk of infection
  • For a full, detailed list, view our report

Market trend

  • Introduction of antimicrobial contact lenses
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Hemoglobinopathies Global Clinical Trials Review, H2, 2017

Hemoglobinopathies Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemoglobinopathies Global Clinical Trials Review, H2, 2017" provides an overview of Hemoglobinopathies clinical trials scenario. This report provides top line data relating to the clinical trials on Hemoglobinopathies. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Hepatic Injury Global Clinical Trials Review, H2, 2017

Hepatic Injury Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Injury Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.......
$2500

Hemoglobinuria Global Clinical Trials Review, H2, 2017

Hemoglobinuria Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemoglobinuria Global Clinical Trials Review, H2, 2017" provides an overview of Hemoglobinuria clinical trials scenario. This report provides top line data relating to the clinical trials on Hemoglobinuria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H2, 2017

Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Liver Failure (Hepatic Insufficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Failure (Hepatic Insufficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are ......
$2500

Hernia Global Clinical Trials Review, H2, 2017

Hernia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hernia Global Clinical Trials Review, H2, 2017" provides an overview of Hernia clinical trials scenario. This report provides top line data relating to the clinical trials on Hernia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Hemophagocytic Lymphohistiocytosis Global Clinical Trials Review, H2, 2017

Hemophagocytic Lymphohistiocytosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemophagocytic Lymphohistiocytosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemophagocytic Lymphohistiocytosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophagocytic Lymphohistiocytosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......
$2500

Hepatic Veno Occlusive Disease Global Clinical Trials Review, H2, 2017

Hepatic Veno Occlusive Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Veno Occlusive Disease Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Veno Occlusive Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Veno Occlusive Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500